197 related articles for article (PubMed ID: 22240462)
1. Higher SLPI expression, lower immune activation, and increased frequency of immune cells in a cohort of Colombian HIV-1 controllers.
Taborda NA; Cataño JC; Delgado JC; Rugeles MT; Montoya CJ
J Acquir Immune Defic Syndr; 2012 May; 60(1):12-9. PubMed ID: 22240462
[TBL] [Abstract][Full Text] [Related]
2. Disease Progression in HIV-1-Infected Viremic Controllers.
Groves KC; Bibby DF; Clark DA; Isaksen A; Deayton JR; Anderson J; Orkin C; Stagg AJ; McKnight A
J Acquir Immune Defic Syndr; 2012 Dec; 61(4):407-16. PubMed ID: 22902723
[TBL] [Abstract][Full Text] [Related]
3. Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers.
Julg B; Pereyra F; Buzón MJ; Piechocka-Trocha A; Clark MJ; Baker BM; Lian J; Miura T; Martinez-Picado J; Addo MM; Walker BD
Clin Infect Dis; 2010 Jul; 51(2):233-8. PubMed ID: 20550452
[TBL] [Abstract][Full Text] [Related]
4. A correlate of HIV-1 control consisting of both innate and adaptive immune parameters best predicts viral load by multivariable analysis in HIV-1 infected viremic controllers and chronically-infected non-controllers.
Tomescu C; Liu Q; Ross BN; Yin X; Lynn K; Mounzer KC; Kostman JR; Montaner LJ
PLoS One; 2014; 9(7):e103209. PubMed ID: 25078947
[TBL] [Abstract][Full Text] [Related]
5. Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses?
Blankson JN
Antiviral Res; 2010 Jan; 85(1):295-302. PubMed ID: 19733595
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional profiling of CD4 T cells identifies distinct subgroups of HIV-1 elite controllers.
Vigneault F; Woods M; Buzon MJ; Li C; Pereyra F; Crosby SD; Rychert J; Church G; Martinez-Picado J; Rosenberg ES; Telenti A; Yu XG; Lichterfeld M
J Virol; 2011 Mar; 85(6):3015-9. PubMed ID: 21177805
[TBL] [Abstract][Full Text] [Related]
7. Higher Frequency of NK and CD4+ T-Cells in Mucosa and Potent Cytotoxic Response in HIV Controllers.
Taborda NA; González SM; Alvarez CM; Correa LA; Montoya CJ; Rugeles MT
PLoS One; 2015; 10(8):e0136292. PubMed ID: 26291824
[TBL] [Abstract][Full Text] [Related]
8. Increased alpha-defensins 1-3 production by dendritic cells in HIV-infected individuals is associated with slower disease progression.
Rodríguez-García M; Climent N; Oliva H; Casanova V; Franco R; Leon A; Gatell JM; García F; Gallart T
PLoS One; 2010 Feb; 5(2):e9436. PubMed ID: 20195543
[TBL] [Abstract][Full Text] [Related]
9. CD8+ T Cell Breadth and Ex Vivo Virus Inhibition Capacity Distinguish between Viremic Controllers with and without Protective HLA Class I Alleles.
Koofhethile CK; Ndhlovu ZM; Thobakgale-Tshabalala C; Prado JG; Ismail N; Mncube Z; Mkhize L; van der Stok M; Yende N; Walker BD; Goulder PJR; Ndung'u T
J Virol; 2016 Aug; 90(15):6818-6831. PubMed ID: 27194762
[TBL] [Abstract][Full Text] [Related]
10. Particular activation phenotype of T cells expressing HLA-DR but not CD38 in GALT from HIV-controllers is associated with immune regulation and delayed progression to AIDS.
Gonzalez SM; Taborda NA; Correa LA; Castro GA; Hernandez JC; Montoya CJ; Rugeles MT
Immunol Res; 2016 Jun; 64(3):765-74. PubMed ID: 26724942
[TBL] [Abstract][Full Text] [Related]
11. Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine.
Van Braeckel E; Desombere I; Clement F; Vandekerckhove L; Verhofstede C; Vogelaers D; Leroux-Roels G
Vaccine; 2013 Aug; 31(36):3739-46. PubMed ID: 23707169
[TBL] [Abstract][Full Text] [Related]
12. HIV controllers with different viral load cutoff levels have distinct virologic and immunologic profiles.
Côrtes FH; Passaes CP; Bello G; Teixeira SL; Vorsatz C; Babic D; Sharkey M; Grinsztejn B; Veloso V; Stevenson M; Morgado MG
J Acquir Immune Defic Syndr; 2015 Apr; 68(4):377-385. PubMed ID: 25564106
[TBL] [Abstract][Full Text] [Related]
13. Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study.
Potter SJ; Lacabaratz C; Lambotte O; Perez-Patrigeon S; Vingert B; Sinet M; Colle JH; Urrutia A; Scott-Algara D; Boufassa F; Delfraissy JF; Thèze J; Venet A; Chakrabarti LA
J Virol; 2007 Dec; 81(24):13904-15. PubMed ID: 17928341
[TBL] [Abstract][Full Text] [Related]
14. Relationships of PBMC microRNA expression, plasma viral load, and CD4+ T-cell count in HIV-1-infected elite suppressors and viremic patients.
Witwer KW; Watson AK; Blankson JN; Clements JE
Retrovirology; 2012 Jan; 9():5. PubMed ID: 22240256
[TBL] [Abstract][Full Text] [Related]
15. Whole Exome Sequencing of HIV-1 long-term non-progressors identifies rare variants in genes encoding innate immune sensors and signaling molecules.
Nissen SK; Christiansen M; Helleberg M; Kjær K; Jørgensen SE; Gerstoft J; Katzenstein TL; Benfield T; Kronborg G; Larsen CS; Laursen A; Pedersen G; Jakobsen MR; Tolstrup M; Mogensen TH
Sci Rep; 2018 Oct; 8(1):15253. PubMed ID: 30323326
[TBL] [Abstract][Full Text] [Related]
16. Brief Report: Identification of Elite and Viremic Controllers From a Large Urban HIV Ambulatory Center in Kampala, Uganda.
Kayongo A; Gonzalo-Gil E; Gümüşgöz E; Niwaha AJ; Semitala F; Kalyesubula R; Bagaya BS; Joloba ML; Sutton RE
J Acquir Immune Defic Syndr; 2018 Nov; 79(3):394-398. PubMed ID: 30063647
[TBL] [Abstract][Full Text] [Related]
17. CD4 T-cell regeneration in HIV-1 elite controllers.
Yang Y; Al-Mozaini M; Buzon MJ; Beamon J; Ferrando-Martinez S; Ruiz-Mateos E; Rosenberg ES; Pereyra F; Yu XG; Lichterfeld M
AIDS; 2012 Mar; 26(6):701-6. PubMed ID: 22301416
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of Virologic Control and Clinical Characteristics of HIV+ Elite/Viremic Controllers.
Gonzalo-Gil E; Ikediobi U; Sutton RE
Yale J Biol Med; 2017 Jun; 90(2):245-259. PubMed ID: 28656011
[TBL] [Abstract][Full Text] [Related]
19. Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals.
Weber J; Gibson RM; Sácká L; Strunin D; Hodek J; Weberová J; Pávová M; Alouani DJ; Asaad R; Rodriguez B; Lederman MM; Quiñones-Mateu ME
AIDS Res Ther; 2017; 14():15. PubMed ID: 28331526
[TBL] [Abstract][Full Text] [Related]
20. Immunogenic and tolerogenic signatures in human immunodeficiency virus (HIV)-infected controllers compared with progressors and a conversion strategy of virus control.
Whittall T; Peters B; Rahman D; Kingsley CI; Vaughan R; Lehner T
Clin Exp Immunol; 2011 Nov; 166(2):208-17. PubMed ID: 21985367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
